retatrutide triple agonist gip glp-1 glucagon phase 3 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide in Obesity and Diabetes

Results showed a steady increase in glutathione levels when compared to the baseline

G.Maher TaieD.MotaweaS

Over the past year, the clinical and regulatory landscape of GLP-1s has evolved with new indications and approvals expanding their use

In clinical trials, GLP-1 RAs were shown to significantly lower blood pressure (BP) in addition to HbA1c and body weight (BW), indicating the possibility as anti-hypertensive medication of type 2 DM individuals

Parasites et maladies : reprer sans paniquer (mais agir quand mme) On croit toujours que "a narrive quaux autres" jusquau jour o on voit un ide avec des taches bizarres ou qui nage comme sil avait bu la tasse